News

The twice daily tablet ‘Xigduo’ that combines Forxiga (dapagliflozin), a selective and reversible inhibitor of SGLT2, with metformin hydrochloride (HCI), is the first fixed-dose combination of its kind

With the latest license agreement, Novo Nordisk has exclusive rights to commercialize insulin conjugated to HEPtune and non-exclusive rights to leverage the HEPtune technology across other core therapeutic

According to CureVac, RNActive vaccines represent a novel technology to manufacture safe, efficacious and cost-effective vaccines which are protected against elevated temperature as well as inadvertent freezing. RNActive

Through the collaboration, the companies identified a novel lead series of pan-metallo beta-lactamase inhibitors, which in combination with carbapenems, restores antibacterial activity against life-threatening clinical isolates while exhibiting

According to Bayer, Adempas is currently the only treatment approved for use in two rare types of pulmonary hypertension (PH) – PAH and chronic thromboembolic pulmonary hypertension (CTEPH).

The company has established regional hubs in Singapore and Japan to better enable the industry’s growing need to conduct clinical trials in Asia and/or manage global trials from

Macular Health president and CEO Jeffery McAnnally will announce the new product at the 2014 Optometry’s Marketplace at SECO International in Atlanta, Georgia, on 14 March 2014. McAnnally

An action letter is anticipated before the end of 2014. Carbella is the proposed US trade name for intravenous carbamazepine. Oral carbamazepine is an important treatment option for

The trial met its primary efficacy endpoint of a statistically significant improvement in kidney function. Specifically, a dose of 1.5mg/m2 led to a statistically significant (p=0.045) increase in